Knowledge of food and drug administration reportable deviationsLAM, Rebecca; BRYANT, Barbara J.Transfusion (Philadelphia, PA). 2011, Vol 51, Num 7, pp 1619-1623, issn 0041-1132, 5 p., 2Article

US food and drug administration pushed to changeMCCARTY, Michael.Lancet (British edition). 2006, Vol 367, Num 9523, issn 0140-6736, 1630,1643-1644 [3 p.]Article

FDA Perspective on Companion Diagnostics: An Evolving Paradigm : PRECISION MEDICINEMANSFIELD, Elizabeth A.Clinical cancer research (Print). 2014, Vol 20, Num 6, pp 1453-1457, issn 1078-0432, 5 p.Article

Why the FDA can't protect the publicLENZER, Jeanne; BROWNLEE, Shannon.BMJ (Overseas and retired doctors ed.). 2010, Vol 341, Num 7780, pp 966-968, issn 1759-2151, 3 p.Article

Role of the Food and drug Administration in the use of molecular techniques in immunohematologyKOCHMAN, Sheryl A.Transfusion (Philadelphia, PA). 2007, Vol 47, Num 1S, issn 0041-1132, 3S-9S, SUPConference Paper

A food and drug administration primer : Drug evaluation in the United States, Canada, and the European UnionSIMON, Lee S.Arthritis care and research. 2006, Vol 55, Num 1, pp 4-8, issn 0893-7524, 5 p.Article

The Food and Drug Administration's Drug Safety Oversight Board: An Evolving Paradigm for Clinical Input on Drug SafetyTopicsGRANDINETTI, C. A; OSBORNE, S. F.Clinical pharmacology and therapeutics. 2010, Vol 88, Num 2, pp 269-274, issn 0009-9236, 6 p.Article

The FDA and New Safety WarningsMOORE, Thomas J; SINGH, Sonal; FURBERG, Curt D et al.Archives of internal medicine (1960). 2012, Vol 172, Num 1, pp 78-80, issn 0003-9926, 3 p.Article

Mainstreaming healthy foodsHOLLINGSWORTH, P.Food technology (Chicago). 1997, Vol 51, Num 3, pp 55-58, issn 0015-6639Article

U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009MORGAN-LINNELL, Sonia K; STEWART, David J; KURZROCK, Razelle et al.Clinical cancer research (Print). 2014, Vol 20, Num 13, pp 3364-3370, issn 1078-0432, 7 p.Article

Financial disclosures of scientific papers presented at the 2003 RSNA annual meeting : Association with reporting of non-food and drug administration- approved uses of industry productsBROWN, Stephen D; DALY, Jennifer C; KALISH, Leslie A et al.Radiology. 2006, Vol 239, Num 3, pp 849-855, issn 0033-8419, 7 p.Article

Innovation, Regulation, and the FDAHAMBURG, Margaret A.The New England journal of medicine. 2010, Vol 363, Num 23, pp 2228-2232, issn 0028-4793, 5 p.Article

The FDA Reboot of Antibiotic DevelopmentSHLAES, David M; SAHM, Dan; OPIELA, Carol et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 10, pp 4605-4607, issn 0066-4804, 3 p.Article

Biclustering of Adverse Drug Events in the FDA's Spontaneous Reporting SystemHARPAZ, R; PEREZ, H; CHASE, H. S et al.Clinical pharmacology and therapeutics. 2011, Vol 89, Num 2, pp 243-250, issn 0009-9236, 8 p.Article

Regulating Off-Label Drug Use : Rethinking the Role of the FDASTAFFORD, Randall S.The New England journal of medicine. 2008, Vol 358, Num 14, pp 1427-1429, issn 0028-4793, 3 p.Article

Adverse drug events in children: The US food and drug administration perspective : Adverse drug events and adverse drug reactions in pediatrics patientsRODRIGUEZ, William; ROBERTS, Rosemary; MURPHY, Dianne et al.Current therapeutic research. 2001, Vol 62, Num 10, pp 711-723, issn 0011-393XConference Paper

Regulatory, design, and analysis aspects of complex stability studiesFAIRWEATHER, W. R; LIN, T.-Y. D; KELLY, R et al.Journal of pharmaceutical sciences. 1995, Vol 84, Num 11, pp 1322-1326, issn 0022-3549Article

Drug development and the FDA's critical path initiativeWOOSLEY, R. L; COSSMAN, J.Clinical pharmacology and therapeutics. 2007, Vol 81, Num 1, pp 129-133, issn 0009-9236, 5 p.Article

The US food and drug administration cardiorenal advisory panel and the drug approval processRODEN, Dan M; TEMPLE, Robert.Circulation (New York, N.Y.). 2005, Vol 111, Num 13, pp 1697-1702, issn 0009-7322, 6 p.Article

Development of cardiovascular drugs: The U.S. regulatory milieu from the perspective of a participating nonregulatorBORER, Jeffrey S.Journal of the American College of Cardiology. 2004, Vol 44, Num 12, pp 2285-2292, issn 0735-1097, 8 p.Article

Meeting the challenge of FDA's CMC initiativesKARLTON, P.Pharmaceutical technology. 1996, Vol 20, Num 10, pp 90-100, issn 0147-8087, 7 p.Article

Managing change at FDAWECHSLER, J.Pharmaceutical technology. 1999, Vol 23, Num 12, pp 16-24, issn 0147-8087, 5 p.Article

Individual bioequivalence : A review of the FDA draft guidanceCHOW, S.-C.Drug information journal. 1999, Vol 33, Num 2, pp 435-444, issn 0092-8615Conference Paper

23andMe, the Food and Drug Administration, and the Future of Genetic TestingZETTLER, Patricia J; SHERKOW, Jacob S; GREELY, Henry T et al.JAMA internal medicine (Print). 2014, Vol 174, Num 4, pp 493-494, issn 2168-6106, 2 p.Article

Recalls of Foods due to Microbiological Contamination Classified by the U.S. Food and Drug Administration, Fiscal Years 2003 through 2011DEY, Manashi; MAYO, Jonathan A; SAVILLE, Deborah et al.Journal of food protection. 2013, Vol 76, Num 6, pp 932-938, issn 0362-028X, 7 p.Article